Testing for drug resistance in tuberculosis more quickly and accurately
Official title: Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol
Funded at Pza Innovation LLC · NIH-11005406 · Data updated 2026-11-12
This study is working on a quick and dependable test to see if tuberculosis bacteria can resist a key medicine called pyrazinamide, which will help doctors choose the best treatment for patients and improve their health, especially in places where tuberculosis is common.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pza Innovation LLC NIH-funded |
| Lab location | 1 site (Towson, United States) |
| Project start | January 2, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $843,964 |
| NIH project number | 5R44AI181252-02 |
| Project ID | NIH-11005406 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those suspected of having drug-resistant strains.
✕Less likely to help
Patients who do not have tuberculosis or those with other unrelated health conditions may not benefit from this research.
What this research studies
This research focuses on developing a rapid and reliable test for determining the susceptibility of Mycobacterium tuberculosis to pyrazinamide, a key drug in tuberculosis treatment. By creating a standardized protocol for this testing, the research aims to improve the accuracy of identifying drug-resistant tuberculosis cases. This will help healthcare providers make better treatment decisions, ultimately leading to improved patient outcomes. The methodology involves streamlining the testing process to ensure it is both efficient and cost-effective, making it accessible even in high-burden areas.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate treatment for tuberculosis patients, reducing the risk of complications and improving recovery times.
How similar studies have gone: Previous research has shown that improving drug susceptibility testing can significantly enhance treatment outcomes for tuberculosis patients, indicating a promising avenue for this approach.
Where this research is happening
-
Pza Innovation LLC
Towson, United States Active
Researchers
- Principal investigator: Shi, Wanliang — Pza Innovation LLC
- Study coordinator: Shi, Wanliang
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.